Mast cell tumors in the dog

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 3, 2003, Pages 473-489

  London, Cheryl A ^a   Seguin, Bernard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIHISTAMINIC AGENT; ASPARAGINASE; CHLORAMBUCIL; CHYMASE; CIMETIDINE; CORTICOSTEROID; CYCLINE; CYCLOPHOSPHAMIDE; CYPROHEPTADINE; DIPHENHYDRAMINE; FAMOTIDINE; GELATINASE A; GELATINASE B; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E RECEPTOR; KI 67 ANTIGEN; LEUKOTRIENE DERIVATIVE; LOMUSTINE; NITROSOUREA DERIVATIVE; OMEPRAZOLE; PREDNISONE; RANITIDINE; SUCRALFATE; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINBLASTINE;

ANIMAL DISEASE; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; BREED DIFFERENCE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DIGESTIVE SYSTEM ULCER; DOG; HISTOPATHOLOGY; LYMPH NODE BIOPSY; MASTOCYTOMA; NONHUMAN; PLOIDY; PROGNOSIS; REVIEW; SKIN TUMOR; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION; URINALYSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0038756407     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00003-2     Document Type: Review

References (79)

1. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from. Alameda County. J Natl Cancer Inst 1968;40:307-18.
2. Cohen D, Reif JS, Brodey RS, Keiser M. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 1974;34:2859-68.
3. Priester WA. Skin tumors in domestic animals. Data from 12 US and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1973;50:457-66.
4. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. 4th edition. Philadelphia: WB Saunders; 2000. p. 235-67.
5. Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001;25:511-8.
6. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol 1999;11:53-9.
7. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-96.
8. Rebar AH, Boon GD, DeNicola DB. A cytologic comparison of Romanowsky stains and Papanicolaou type stains. II. Cytology of inflammatory and neoplastic lesions. Vet Clin Pathol 1982;11:16-25.
9. Rothwell TL, Howlett CR, Middleton DJ, Griffiths DA, Duff BC. Skin neoplasms of dogs in Sydney. Aust Vet J 1987;64:161-4.
10. Finnie JW, Bostock DE. Skin neoplasia in dogs. Aust Vet J 1979;55:602-4.
11. Brodey RS. Canine and feline neoplasia. Adv Vet Sci Comp Med 1970;14:309-54.
12. Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986;142:1-19.
13. Peters JA. Canine mastocytoma: excess risk as related to ancestry. J Natl Cancer Inst 1969;42:435-43.
14. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumors: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-74.
15. Lombard LS, Moloney JB. Experimental transmission of mast cell sarcoma in dogs. Fed Proc 1959;18:490-5.
16. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037-51.
17. d mice. Am J Pathol 1987;127:191-8.
18. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;633: 213-24.
19. Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990;63:195-201.
20. Tsai M, Takeishi T, Thompson H, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA 1991;88:6382-6.
21. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000;14:517-35.
22. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998;103:740-9.
23. Pignon J-M, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Hematol 1997;96:374-6.
24. Nagata H, Okada T, Worobec AS, Semere T, Metcalfe DD. c-Kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997;113:184-6.
25. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609-14.
26. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-6.
27. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111: 1227-31.
28. Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83:2120-9.
29. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
30. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-6.
31. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
32. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
33. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human non-lymphoid tissues. Cancer Res 1992;52:6139-43.
34. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Co-expression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994;54:3049-53.
35. Stanulla M, Welte K, Hadam MR, Pietsch T. Coexpression of stem cell factor and its receptor c-kit in human malignant glioma cell lines. Acta Neuropathol (Berl) 1995;89: 158-65.
36. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Non-hematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992;80:374-81.
37. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. J Vet Diagn Invest 2001;13:341-5.
38. London CA, Galli SJ, Yuuki T, Hu Z-Q, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-97.
39. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms. J Invest Dermatol 1999;112:165-70.
40. Downing S, Chien MB, Kass PH, Moore PE, London CA. Prevalence and significance of internal tandem duplications in exons 11 and 12 of C-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-23.
41. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-40.
42. Crowe DT, Goodwin MA, Greene CE. Total laryngectomy for laryngeal mast cell tumor in a dog. J Am Anim Hosp Assoc 1986;22:809-16.
43. Patnaik AK, MacEwen EG, Black AP, Luckow S. Extracutaneous mast-cell tumor in the dog. Vet Pathol 1982;19:608-15.
44. Pollack MJ, Flanders JA, Johnson RC. Disseminated malignant mastocytoma in a dog. J Am Anim Hosp Assoc 1991;27:435-40.
45. O'Keefe DA, Couto CG, Burke-Schwartz C, Jacobs RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med 1987;1:75-80.
46. Hottendorf GH, Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A 1967;14:272-81.
47. Thamm DH, Vail DM. Mast cell tumors. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd edition. Philadelphia: WB Saunders; 2001. p. 261-82.
48. Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG, Grauer GF. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med 1990;4:242-6.
49. Howard EB, Sawa TR, Nielsen SW, Kenyon AJ. Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet 1969;6:146-58.
50. McManus PM. Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). JAVMA 1999;215:355-7.
51. Cayatte SM, McManus PM, Miller WH Jr, Scott DW. Identification of mast cells in buffy coat preparations from dogs with inflammatory skin diseases. JAVMA 1995;206:325-6.
52. Bookbinder PF, Butt MT, Harvey HJ. Determination of the number of mast cells in lymph node, bone marrow, and buffy coat cytologic specimens from dogs. JAVMA 1992; 200:1648-50.
53. Hahn KA, King GK, Harris FD, et al. The usefulness of hepatic and splenic fine needle aspiration cytology in the clinical staging of canine cutaneous mast cell tumors. An evaluation of 88 dogs (1987-1998). Proceedings of the Mid-Year Conference of the Veterinary Cancer Society. 2000. p. 23.
54. Leibman NF, Guilpin VO, Fettman MJ, Powers BE, Schochet RA, Withrow SJ. Cytologic comparison of mast cell numbers in liver and spleen of normal dogs and dogs with mast cell tumors. Proceedings of the 19th Annual Veterinary Cancer Society Conference. 1999. p. 28.
55. Siegel S, Cronin KL, Philibert JC, Beck K, Schelling S. Evaluation of a staging protocol for cutaneous mast cell tumors. Proceedings of the Mid-Year Conference of the Veterinary Cancer Society. 2000. p. 22.
56. Simoes JP, Schoning P, Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 1994;31:637-47.
57. Turrel JM, Kitchell BE, Miller LM, Theon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. JAVMA 1988;193:936-40.
58. Frimberger AE, Moore AS, LaRue SM, Gliatto JM, Bengtson AE. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). J Am Anim Hosp Assoc 1997;33:320-4.
59. Abadie JJ, Amardeilh MA, Delverdier ME. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. JAVMA 1999;215:1629-34.
60. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-7.
61. LaDue T, Price GS, Dodge R, Page RL, Thrall DE. Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound 1998;39:57-62.
62. Takahashi T, Kadosawa T, Nagase M, et al. Visceral mast cell tumors in dogs: 10 cases (1982-1997). JAVMA 2000;216:222-6.
63. Kravis LD, Vail DM, Kisseberth WC, Ogilvie GK, Volk LM. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. JAVMA 1996;209:1418-20.
64. Bostock DE, Crocker J, Harris K, Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumors. Br J Cancer 1989;59:915-8.
65. Ayl RD, Couto CG, Hammer AS, Weisbrode S, Ericson JG, Mathes L. Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors. Vet Pathol 1992;29:386-90.
66. Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. J Immunol 1999;162:5528-35.
67. Leibman NF, Lana SE, Hansen RA, et al. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med 2000;14:583-6.
68. Ginn PE, Fox LE, Brower JC, Gaskin A, Kurzman ID, Kubilis PS. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet Pathol 2000;37:33-9.
69. Jaffe MH, Hosgood G, Taylor HW, et al. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet Pathol 2000;37:40-6.
70. Gilson SD, Stone EA. Principles of oncologic surgery. Compend Contin Educ Pract Vet 1990;12:827-39.
71. Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). JAVMA 2001;218:1120-3.
72. Weisse C, Shofer FS, Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 2002;38:71-3.
73. Grier RL, Di Guardo G, Schaffer CB, et al. Mast cell tumor destruction by deionized water. Am J Vet Res 1990;51:1116-20.
74. Jaffe MH, Hosgood G, Kerwin SC, Hedlund CS, Taylor HW. Deionised water as an adjunct to surgery for the treatment of canine cutaneous mast cell tumours. J Small Anim Pract 2000;41:7-11.
75. al-Sarraf R, Mauldin GN, Patnaik AK, Meleo KA. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. J Vet Intern Med 1996;10:376-8.
76. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994;8:406-8.
77. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-5.
78. Elmslie R. Combination chemotherapy with and without surgery for dogs with high grade mast cell tumors with regional lymph node metastases. Vet Cancer Society Newsletter 1996;6-7.
79. McCaw DL, Miller MA, Bergman PJ, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997;11:375-8.